PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
In 2015, the Bradner group has developed the first CRBN-based PROTAC, with the structure of pomalidomide capturing CRBN and BRDs inhibitor JQ1 as POI ligand.
In 2015, the Bradner group has developed the first CRBN-based PROTAC, with the structure of pomalidomide capturing CRBN and BRDs inhibitor JQ1 as POI ligand.
